Special Issue

Innovative Vaccines That Modulate the Immune System to Enhance Cancer Therapy

Message from the Guest Editor

Recent advancements in cancer therapies have highlighted the importance of the immune system in modulating the tumor microenvironment. The therapeutic modalities that enable the immune system to recognize and eliminate cancer include therapeutic vaccines, immune checkpoint blockade, T cell engagers, and adoptive cell therapies. This Special Issue will focus on recent advances in cancer immunotherapies and discuss innovations in therapeutic cancer vaccines and combination strategies that enhance anti-tumor immunity.

Guest Editor

Dr. Ruchi Roy

UICentre for Drug Discovery, College of Pharmacy, University of Illinois Chicago, Chicago, IL 60612, USA

Deadline for manuscript submissions

31 October 2025



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/232717

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

